TSHomas typically have strong SST2 and often SST5 expression and show a good response to first-generation SRIF analogs, with about 10% of cases showing resistance (Beck-Peccoz et al., 2013). The gene discussed is SSTR5; the disease is TSH-secreting pituitary adenoma.